# US 2011/0257127 A1 · A2b adenosine receptor antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0257127 A1
- Document ID: US20110257127A1
- Status: Published application
- Kind: A1
- Application number: 13/169,834
- Filed: 2011-06-27
- Published: 2011-10-20
- Earliest claimed: 2001-11-09
- Assignees: Gilead Sciences, Inc.
- Inventors: Rao Kalla; Thao Perry; Elfatih Elzein; Vaibhav Varkhedkar; Xiaofen Li; Prabha Ibrahim; Venkata Palle; Dengming Xiao; Jeff Zablocki
- Web page: https://patentgrep.com/patent/US20110257127A1

## CPC

- C07D 473/06: with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/12: Antidiarrhoeals
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/06: Antiasthmatics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07D 473/04: two oxygen atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are novel compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.

## Claims

### Claim 1

A method of treating a disease state by inhibition of an adenosine receptor characterized as A2B, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of the formula:
wherein:
R1 and R2 are independently chosen from hydrogen, optionally substituted alkyl, or a group -D-E, in which D is a covalent bond or alkylene, and E is optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted alkenyl, or optionally substituted alkynyl, with the proviso that when D is a covalent bond E cannot be alkoxy;
R3 is hydrogen, optionally substituted alkyl or optionally substituted cycloalkyl;
X is optionally substituted arylene or heteroarylene;
Y is a covalent bond or alkylene in which one carbon atom can be optionally replaced by —O—, —S—, or —NH—, and is optionally substituted by hydroxy, alkoxy, optionally substituted amino, or —COR, in which R is hydroxy, alkoxy or amino;
with the proviso that when the optional substitution is hydroxy or amino said substitution cannot be present on a carbon atom adjacent to a heteroatom; and
Z is hydrogen, optionally substituted monocyclic aryl or optionally substituted monocyclic heteroaryl;
with the proviso that Z is hydrogen only when Y is a covalent bond and X is optionally substituted 1,4-pyrazolone attached to the purine ring by a carbon atom; and,
with the proviso that when X is optionally substituted arylene, Z is an optionally substituted monocyclic heteroaryl other than optionally substituted imidazole.

### Claim 2 (depends on 1)

The method of claim 1, wherein the disease state is chosen from atherosclerosis, angiogenesis, type II diabetes, diabetic retinopathy, cancer, and asthma.

### Claim 3 (depends on 2)

The method of claim 2, wherein the disease state is cancer.

### Claim 4 (depends on 2)

The method of claim 2, wherein the disease state is asthma.

### Claim 5 (depends on 2)

The method of claim 2, wherein the disease state is diabetic retinopathy.

### Claim 6 (depends on 1)

The method of claim 1, wherein the disease state is an inflammatory gastrointestinal tract disorder.

### Claim 7 (depends on 3)

The method of claim 3, wherein the inflammatory gastrointestinal tract disorder is diarrhea.

### Claim 8 (depends on 1)

The method of claim 1, wherein the disease state is a neurological disorder.

### Claim 9 (depends on 5)

The method of claim 5, wherein the neurological disorder is senile dementia, Alzheimer's disease, or Parkinson's disease.

### Claim 10

A method of treating a disease state by inhibition of an adenosine receptor characterized as A2B, comprising administering to a mammal in need thereof a therapeutically effective dose of the compound 3-ethyl-1-propyl-8-{1-[(3-trifluoromethylphenyl)methyl]pyrazol-4-yl}-1,3,7-trihydropurine-2,6-dione.

### Claim 11 (depends on 1)

The method of claim 1, wherein the disease state is chosen from atherosclerosis, angiogenesis, type II diabetes, diabetic retinopathy, cancer, and asthma.

### Claim 12 (depends on 11)

The method of claim 11, wherein the disease state is cancer.

### Claim 13 (depends on 11)

The method of claim 11, wherein the disease state is asthma.

### Claim 14 (depends on 11)

The method of claim 11, wherein the disease state is diabetic retinopathy.

### Claim 15 (depends on 10)

The method of claim 10, wherein the disease state is an inflammatory gastrointestinal tract disorder.

### Claim 16 (depends on 15)

The method of claim 15, wherein the inflammatory gastrointestinal tract disorder is diarrhea.

### Claim 17 (depends on 10)

The method of claim 10, wherein the disease state is a neurological disorder.

### Claim 18 (depends on 17)

The method of claim 17, wherein the neurological disorder is senile dementia, Alzheimer's disease, or Parkinson's disease.
